The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
Clinical trial NCT05868083 · UNKNOWN
Trial details
- NCT number
- NCT05868083
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-24
- Primary completion
- 2024-05-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.